FATE Stock-Based Compensation
Fate Therapeutics Inc · Stock-Based Compensation
FATE Stock-Based Compensation
Latest reported$17.84Mperiod ending
FATE TTM Stock-Based Comp ($1.55M → $17.84M)
TTM stock-based compensation
High-resolution chart · PNG
FATE stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 17,836,000 | |
| 21,472,000 | |
| 24,924,000 | |
| 28,516,000 | |
| 35,420,000 | |
| 37,896,000 | |
| 41,496,000 | |
| 32,376,000 | |
| 30,715,000 | |
| 21,085,000 | |
| 21,087,000 | |
| 21,087,000 | |
| 30,451,000 | |
| 50,993,000 | |
| 59,341,000 | |
| 73,935,000 | |
| 68,007,000 | |
| 60,719,000 | |
| 54,364,000 | |
| 48,531,000 | |
| 42,834,000 | |
| 36,816,000 | |
| 30,753,000 | |
| 26,575,000 | |
| 23,305,000 | |
| 20,455,000 | |
| 17,410,000 | |
| 14,611,000 | |
| 11,680,000 | |
| 8,779,000 | |
| 6,293,000 | |
| 5,404,000 | |
| 4,633,000 | |
| 4,121,000 | |
| 3,606,000 | |
| 3,530,000 | |
| 3,441,000 | |
| 3,254,000 | |
| 3,184,000 | |
| 2,845,000 | |
| 2,637,000 | |
| 2,589,000 | |
| 2,400,000 | |
| 2,532,000 | |
| 2,485,000 | |
| 2,171,000 | |
| 2,434,000 | |
| 2,207,000 | |
| 2,662,000 | |
| 2,350,000 | |
| 1,554,000 | |
| 1,218,000 | |
| 278,000 |